SCHEMBL7190967

SCHEMBL7190967

COC(=O)c1cnc2c(c1)[nH]c(=O)n2[C@H]1CC[C@H](O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.49
JAK2 O60674 3/20 0.45
JAK1 P23458 3/20 0.45
JAK3 P52333 3/20 0.45
TPH1 P17752 1/20 0.43
TPH2 Q8IWU9 1/20 0.43
PIK3CA P42336 2/20 0.42
MTOR P42345 1/20 0.42
TNKS O95271 2/20 0.39
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 3/20 0.39
HTT P42858 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.39
PKM P14618 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 1/20 0.39
TNKS2 Q9H2K2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7190974 1.00 PRKDC (0.49) PRKDCJAK2JAK1JAK3TPH1
SCHEMBL20468291 0.95 PRKDC (0.43) PRKDCJAK2JAK1JAK3TPH1
SCHEMBL7184792 0.79 ALDH1A1 (0.54) TPH1TPH2ALDH1A1KDM4EHTT
SCHEMBL7184789 0.79 ALDH1A1 (0.54) TPH1TPH2ALDH1A1KDM4EHTT
SCHEMBL26350854 0.78 PLAT (0.40) JAK2JAK1JAK3TPH1TPH2
SCHEMBL7182076 0.75 TNKS (0.57) PRKDCJAK2JAK1JAK3TPH1
SCHEMBL7182072 0.75 TNKS (0.57) PRKDCJAK2JAK1JAK3TPH1
SCHEMBL30534158 0.74 PIK3CA (0.41) PRKDCPIK3CAMTORKDM4E
SCHEMBL27153219 0.74 PIK3CA (0.41) PRKDCPIK3CAMTORKDM4E
SCHEMBL18477021 0.73 ALDH1A1 (0.58) ALDH1A1KDM4EHTTKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed